Company Overview

Check-Cap Ltd. is a medical technology company focused on the development of non-invasive screening solutions for colorectal cancer. The company operates within the diagnostic medical devices and digital health industries, with its core technology designed to improve patient compliance with colorectal cancer screening through a swallowable capsule system. Its primary product candidate has been the C-Scan system, an ingestible capsule intended to image the colon without the need for bowel preparation or sedation.

The company was founded in Israel and advanced its technology through clinical trials in the United States and Europe, targeting healthcare providers and screening programs serving average-risk populations. Check-Cap’s strategic positioning has centered on reducing barriers to screening compared with colonoscopy and fecal-based tests. The company has historically operated as a development-stage enterprise without recurring commercial revenue. Public disclosures indicate that following regulatory setbacks and capital constraints, the company significantly reduced or ceased active operations. The ultimate disposition of its technology and corporate status is data inconclusive based on available public sources, as disclosures vary by reporting period.

Business Operations

Check-Cap’s operations historically consisted of a single reportable business segment focused on the research, development, and clinical validation of the C-Scan system. Revenue generation was not material, with funding primarily derived from equity offerings and grants rather than product sales, as reflected in its SEC filings. The company did not report meaningful commercial operations prior to its operational wind-down.

Operational activities were concentrated on capsule engineering, imaging software development, and multicenter clinical trials, particularly in the United States. Manufacturing and certain development activities were supported through third-party contractors rather than vertically integrated facilities. The company maintained subsidiaries including Check-Cap Medical Ltd. in Israel, which served as the primary research and development arm.

Strategic Position & Investments

Strategically, Check-Cap aimed to position itself as a disruptive alternative in colorectal cancer screening by addressing patient adherence, a key limitation of existing screening modalities. Its growth initiatives focused on achieving U.S. Food and Drug Administration (FDA) approval and pursuing partnerships with large healthcare or diagnostics companies to commercialize the technology.

Public disclosures indicate that the company explored strategic alternatives, including asset sales, licensing arrangements, or mergers, following unfavorable regulatory developments and liquidity challenges. Any completed transactions, asset divestitures, or ongoing investment activities related to the C-Scan technology are data inconclusive based on available public sources, as reporting after its operational wind-down has been limited and inconsistent.

Geographic Footprint

Check-Cap maintained its corporate headquarters in Israel, with significant clinical and regulatory activity conducted in the United States. Clinical trial sites and regulatory engagement were primarily U.S.-focused, reflecting the importance of FDA approval to the company’s strategy.

Beyond Israel and the United States, the company reported limited operational presence, with some clinical and feasibility activities in Europe. It did not disclose material revenue-generating international operations, and its global footprint remained largely research- and trial-oriented rather than commercial.

Leadership & Governance

Check-Cap was founded by Israeli entrepreneurs and scientists with backgrounds in medical imaging and diagnostics. Leadership and board composition evolved over time, particularly as the company transitioned from growth to strategic review and operational reduction.

Key executives disclosed in the company’s most recent publicly available filings include:

• Yoav Kimchy – Former Chief Executive Officer
• Alex Ovadia – Chief Executive Officer
• Jonathan Salzman – Chief Financial Officer
• Amir Fishelovitz – Chairman of the Board

The leadership’s stated philosophy, as reflected in public filings and investor communications, emphasized innovation in preventive healthcare and capital discipline; however, later governance actions focused on preserving shareholder value amid financial and regulatory constraints. Certain executive roles and current governance status are data inconclusive based on available public sources due to limited recent disclosures.